Why do the latest guidelines on the treatment of hypertension (PTNT 2015) indicate that telmisartan, as an exception among ARBs, should be the drug of choice in patients with hypertension and multiple cardiovascular risk factors Komentarz

##plugins.themes.bootstrap3.article.sidebar##

Dostęp przez subskrypcję PDF (English)


Opublikowane: mar 31, 2016
Słowa kluczowe:
hypertension, cardiovascular risk, ARB, telmisartan

##plugins.themes.bootstrap3.article.main##

Marek Chmielewski
Department and Clinic of Cardiology, Arterial Hypertension and Internal Medicine, Second Faculty of Medicine, Medical University of Warsaw
Marek Kuch
Department and Clinic of Cardiology, Arterial Hypertension and Internal Medicine, Second Faculty of Medicine, Medical University of Warsaw

Abstrakt

The efficacy of telmisartan for cardiovascular prevention in high-risk patients has been confirmed in the ONTARGET study. Telmisartan is as efficacious as ACE inhibitors (ramipril), which has ensured its high position in the current PTNT recommendations (2015).

##plugins.themes.bootstrap3.article.details##

Jak cytować
Chmielewski , M., & Kuch, M. (2016). Why do the latest guidelines on the treatment of hypertension (PTNT 2015) indicate that telmisartan, as an exception among ARBs, should be the drug of choice in patients with hypertension and multiple cardiovascular risk factors. Medycyna Faktów , 9(1(30), 30-31. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2264
Numer
Tom 9 Nr 1(30) (2016)
Dział
Artykuły

Copyright © by Medical Education. All rights reserved.

Bibliografia

1. HOPE Study Investigators. N Engl J Med 2000; 342: 145-153.
2. The ONTARGET Investigators. N Engl J Med 2008; 358: 1547-1559.
3. Management of Arterial Hypertension. 2015 Guidelines of the Polish Society of Arterial Hypertension; 1(1): 1-70.